A second limitation is that DWI would not normally be the method of choice to classify AD stages; structural atrophy, or amyloid and tau proteins measured in the blood or CSF tends to be favored, because of the known pathology of the disease. The gene discussed is MAPT; the disease is Alzheimer disease.